The A.A.O. recommends that adults with no signs or risk factors for eye disease get a comprehensive exam at 40 to establish a ...

We present one of the first comprehensive evaluations of predictive information derived from retinal fundus photographs, illustrating the potential and limitations of readily accessible and low-cost ...

The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press ...

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

Scientists found that protein deposits in the retina create unique light patterns for different brain diseases in humans.

March 17 (Reuters) - The U.S. Food and Drug Administration declined to approve Aldeyra Therapeutics' drug for a type of eye ...

A 2026 company-issued report outlining Retina Clear's 'Red Root Hack' marketing narrative, ingredient research context, ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

Eye Cancer, Known Medically as Retinoblastoma, Is a Rare Eye Disease Retinoblastoma is a rare eye disease that primarily occurs in childhood and can affect one or both eyes. One of the most common ...

Women over 50 face increased eye health risks post-menopause due to hormonal shifts. Conditions like dry eye, cataracts, glaucoma, and age-related macular degeneration become more prevalent.

With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease ...